| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6113714 | Critical Reviews in Oncology/Hematology | 2013 | 31 Pages |
Abstract
Lenalidomide is recommended as first line therapy in lower risk del5q MDS. There is insufficient evidence to recommend lenalidomide for treatment of higher risk del5q MDS or AML, or for any risk non-del5q MDS or AML. Combining lenalidomide with other agents is not recommended. Thalidomide is not recommended.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Heather A. Leitch, Rena Buckstein, April Shamy, John M. Storring,